Citigroup Increases Quest Diagnostics (NYSE:DGX) Price Target to $145.00

Quest Diagnostics (NYSE:DGX – Free Report) had its target price upped by Citigroup from $135.00 to $145.00 in a report released on Wednesday, Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock. Other research analysts have also recently issued research reports about the stock. SVB Leerink initiated coverage on […]

Related Keywords

Czech Republic ,United States ,Czech ,Michaele Prevoznik ,Catherinet Doherty , ,Czech National Bank ,Exchange Traded Concepts ,Montecito Bank ,Quest Diagnostics ,Barclays ,Mendota Financial Group ,Quest Diagnostics Company Profile ,Citigroup ,Quest Diagnostics Incorporated ,Naples Global Advisors ,Free Report ,Get Free Report ,National Bank ,Financial Group ,Traded Concepts ,Global Advisors ,Diagnostics Incorporated ,Quest Diagnostics Daily ,